Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Conditions:   Esophageal Neoplasms;   Lung Neoplasms;   Mesothelioma;   Thymus Neoplasms;   Neoplasms, Germ Cell and Embryonal
Intervention:   Drug: Mithramycin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2016

from #ENT via xlomafota13 on Inoreader http://ift.tt/2aZk805
via IFTTT